External radiotherapy for carcinoma of the eyelid: Report of 850 cases treated

Schlienger, P; Brunin, F.; Desjardins, Laurence; Laurent, Michel; Haye, C; Vilcoq, J.R.

doi:10.1016/0360-3016(95)02135-3

Cited by 40 publications

(40 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fitzpatrick et al 6 reported that 9.6% of patients had significant changes after radiotherapy with superficial X-rays for carcinoma of the eyelid, including skin atrophy, eyelid disfigurement, epiphora, keratitis, cataract, and globe perforation. Schlienger et al 9 reported a 30% sequelae rate after eyelid irradiation with superficial X-rays or electrons and a 1.4% rate of serious ocular complications. The site and extent of the tumor obviously affect the ocular side effects.…”

Section: Discussionmentioning

confidence: 99%

“…Controversy exists as to whether surgery alone, radiotherapy alone, or a combination of surgery with postoperative radiotherapy is the most appropriate treatment for eyelid lesions, particularly when the primary goal is to achieve locoregional control while preserving function and cosmesis. 2,3,9,10 Studies of outcomes to date have included relatively small numbers of patients due to the rarity of the disease. Therefore, the natural history of SCC of the eyelid after treatment requires further clarification.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Outcomes after radiotherapy for squamous cell carcinoma of the eyelid

Petsuksiri

Frank

Garden

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND. Squamous cell carcinoma (SCC) of the eyelid is a rare malignancy with metastatic potential. In the current study, the outcomes of patients with SCC of the eyelid were evaluated after definitive and postoperative radiation therapy. METHODS. The medical records of all patients treated with radiotherapy for SCC of the eyelid at 1 institution between 1950 and 2005 were reviewed. Patient records were analyzed for clinical characteristics, pathologic features, radiation techniques, and outcomes. Survival rates were calculated using the Kaplan‐Meier method; factors affecting survival were assessed using the log‐rank test. RESULTS. During the study period, 39 patients with 42 eyelid SCCs were treated with radiotherapy. Thirty‐two tumors were treated with primary radiotherapy and 10 were treated with postoperative radiotherapy after wide local excision. Surviving patients were followed for a median of 76 months. The 5‐year disease‐specific and overall survival rates for all patients were 86% and 71%, respectively. At 5 years, local, regional, and distant disease control rates for all tumors were 88%, 95%, and 97%, respectively. There were no significant differences in the 5‐year local, regional, and distant control rates between tumors treated with definitive and those treated with postoperative radiotherapy. There were no grade 3 or 4 complications. CONCLUSIONS. Primary radiotherapy for SCC of the eyelid provides excellent locoregional control with reasonable complication rates and should be considered an alternative to surgery in selected patients. Cancer 2008. © 2007 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Outcomes after radiotherapy for squamous cell carcinoma of the eyelid

Petsuksiri

Frank

Garden

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…Basal cell carcinoma (BCC) is the most common, comprising about 80% of all nonmelanoma skin cancers (Scotto et al 1983) and is also the most common skin malignancy of the eyelid and the periocular region (±80%) (Fitzpatrick et al 1984;Schlienger et al 1996;Mamalis et al 1989). The pathogenesis of BCC includes both environmental and hereditary factors.…”

Section: Photodynamic Therapy Utilising Topical D-aminolevulinic Acidmentioning

confidence: 99%

“…There are several treatment modalities for BCCs in the eye close region and the cure rate is often reported to be greater than 90% (Anderson & Ceilley 1978;Chalfin & Putterman 1979;Doxanas et al 1981;Frank 1989;Fraunfelder et al 1984;Lederman 1976;Schlienger et al 1996). Although a good tumour response is obtained for all methods, the optimal treatment modality is still under consideration and many trials suffer from short followup periods.…”

Section: Photodynamic Therapy Utilising Topical D-aminolevulinic Acidmentioning

confidence: 99%

Photodynamic therapy utilising topical δ‐aminolevulinic acid in non‐melanoma skin malignancies of the eyelid and the periocular skin

Wang

Bauer

Andersson‐Engels

et al. 1999

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…However, patients developed significant complications within the radiation field such as madarosis, epiphora, ocular surface disorders and conjunctival scarring [3]. When eyelid tumors (1-4 cm size) were treated by electron beam therapy at a dose of 45-70 Gy in daily fractions of 2-4 Gy, though there was reasonable local tumor regression, few cases had recurrences (11%) and few had local radiation side effects such as skin atrophy and mild deformities [4].EBRT can be considered another option for treating the eyelid tumors [5][6][7]. Primary eyelid tumors when treated with median radiation dose of 60 Gy in 30 fractions (range 50 to 66.6 Gy/ 22 to 37 fractions), the local-progression-free and disease-free-survival rate at 5 years was 93% and 80%, respectively.…”

mentioning

confidence: 99%

What is New in the Treatment of Eyelid Tumors with Radiation Therapy?

Turaka¹,

Turaka²,

Koneru³

2016

OMICS J Radiol

View full text Add to dashboard Cite

EditorialMalignant tumors of the eyelids can cause considerable functional and aesthetic complications. Most common eyelid tumor is basal cell carcinoma (BCC) followed by squamous cell carcinoma, sebaceous gland carcinoma, Merkel cell carcinoma and malignant melanoma (rare) [1]. They can be located at lower eyelid (most common site) or upper eyelid, outer canthus and inner canthus. Surgical excision is the standard primary treatment option for the eyelid tumors. However, in cases with incompletely excised primary tumors, recurrent tumors, or inoperable large primary tumors and elderly patients who cannot tolerate general anesthesia with significant co-morbidities, radiation therapy (RT) is considered as an effective alternative/adjuvant treatment modality [2][3][4][5][6][7]. Different radiation therapeutic methods such as external beam radiotherapy (EBRT) with x-rays [superficial (45-100 Kv), orthovoltage (100-250 Kv)] or megavoltage photons & electrons and radionuclide plaque brachytherapy has been used to treat various eyelid tumors with good success [2][3][4][5][6][7][8][9]. However, acute and chronic radiation side-effects (skin reactions, eyelid telangiectasia, eyelid atrophy, eyelash loss (madarosis), epiphora (tearing), ocular surface disorders (dry eyes), cataract, radiation papillopathy, retinopathy & maculopathy and second malignant neoplasms) can lead to significant functional and visual disabilities. Recently new techniques to precisely deliver the radiation to the target tumor has been developed that prevent damage to the surrounding healthy tissues and cause minimal radiation toxicities. Currently, interstitial highdose-rate (HDR) brachytherapy and electronic surface brachytherapy (ESB) are the new techniques being used to treat various nonmelanoma skin malignancies including the eyelid carcinomas [10][11][12][13][14][15].Contact X-ray radiotherapy (50 kV) was used in the past to treat the small (<2 cm) eyelid tumors. At a dose of 42 Gray (Gy)/7 fractions/ 4 weeks, there was excellent regression of the tumors with long-term tumor control in 98%. However, loss of eye lashes, punctal stenosis, skin depigmentation was noticed even at doses of 1 or 2 fractions of 6 Gy per week. Also local tumor relapse was seen in few cases around the irradiated area. The cosmetic results were good with x-ray RT [2]. Following orthovoltage radiotherapy of medial canthal BCC, 10-year tumor control rate was 94% with no recurrence rates. However, patients developed significant complications within the radiation field such as madarosis, epiphora, ocular surface disorders and conjunctival scarring [3]. When eyelid tumors (1-4 cm size) were treated by electron beam therapy at a dose of 45-70 Gy in daily fractions of 2-4 Gy, though there was reasonable local tumor regression, few cases had recurrences (11%) and few had local radiation side effects such as skin atrophy and mild deformities [4].EBRT can be considered another option for treating the eyelid tumors [5][6][7]. Primary eyelid tumors when treated with median radiatio...

show abstract

External radiotherapy for carcinoma of the eyelid: Report of 850 cases treated

Cited by 40 publications

References 29 publications

Outcomes after radiotherapy for squamous cell carcinoma of the eyelid

Outcomes after radiotherapy for squamous cell carcinoma of the eyelid

Photodynamic therapy utilising topical δ‐aminolevulinic acid in non‐melanoma skin malignancies of the eyelid and the periocular skin

What is New in the Treatment of Eyelid Tumors with Radiation Therapy?

Contact Info

Product

Resources

About